Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for Capricor Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will earn ($1.27) per share for the year, down from their prior forecast of ($0.84). Cantor Fitzgerald currently has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($0.83) per share.
Several other research analysts have also issued reports on CAPR. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research report on Tuesday. LADENBURG THALM/SH SH increased their price objective on Capricor Therapeutics from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, StockNews.com cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.
Read Our Latest Research Report on CAPR
Capricor Therapeutics Price Performance
CAPR traded up $0.31 on Thursday, hitting $5.64. The company had a trading volume of 497,758 shares, compared to its average volume of 300,903. The stock has a fifty day simple moving average of $5.93 and a 200-day simple moving average of $4.61. The firm has a market capitalization of $177.66 million, a P/E ratio of -6.51 and a beta of 4.06. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $8.22.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.21. The firm had revenue of $12.09 million during the quarter, compared to analysts' expectations of $5.80 million. Capricor Therapeutics had a negative net margin of 89.72% and a negative return on equity of 309.81%.
Hedge Funds Weigh In On Capricor Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of CAPR. BNP Paribas Financial Markets purchased a new stake in Capricor Therapeutics during the 1st quarter valued at about $40,000. Jump Financial LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth approximately $258,000. Citigroup Inc. purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $211,000. Finally, Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after buying an additional 200,499 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
